A patient with hereditary angioedema who experienced anaphylaxis in response to C1 esterase inhibitor is successfully treated with DX-88 (Ecallantide1), a potent human plasma kallikrein inhibitor:: A case study

被引：2

作者：

Cicardi, Marco ^{[1
]}

Zingale, Lorenza C. ^{[1
]}

Zanichelli, Andrea ^{[1
]}

机构：

[1] Univ Milan, Osped San Giuseppe AFaR, Ist Med Interna, Milan, Italy

来源：

MOLECULAR IMMUNOLOGY | 2007年 / 44卷 / 1-3期

关键词：

D O I：

10.1016/j.molimm.2006.07.036

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：160 / 161

页数：2

共 50 条

[1] Resolution of bowel obstruction in a patient with hereditary angioedema treated with DX-88 (Ecallantide1), a potent human plasma kallikrein inhibitor:: A case study
Cicardi, Marco
Zingale, Lorenza C.
Zanichelli, Andrea
[J]. MOLECULAR IMMUNOLOGY, 2007, 44 (1-3) : 160 - 160
[2] Anaphylaxis in response to C1 esterase inhibitor in a patient with hereditary Angioedema - Successful treatment with DX-88, a human plasma kallikrein inhibitor
Zingale, Lorenza C.
Zanichelli, Andrea
Deliliers, Daniela Lambertenghi
Cicardi, Marco
[J]. ALLERGY & CLINICAL IMMUNOLOGY INTERNATIONAL-JOURNAL OF THE WORLD ALLERGY ORGANIZATION, 2007, 19 (04): : 159 - 163
[3] Inhibitor of human plasma kallikrein DX-88 for the treatment of acute attack in a family with hereditary angioedema
Anne, R
Deveras, E
Bracho, F
[J]. BLOOD, 2004, 104 (11) : 113B - 114B
[4] A case of normal C1 esterase inhibitor hereditary angioedema successfully treated with berotralstat
Kelbel, Theodore
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 128 (04) : 462 - +
[5] Idiopathic nonhistaminergic angioedema successfully treated with ecallantide, icatibant, and C1 esterase inhibitor replacement
Stahl, Mark C.
Harris, Caitlin K.
Matto, Sulaiman
Bernstein, Jonathan A.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2014, 2 (06): : 818 - 819
[6] Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery
Lehmann, Andreas
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (08) : 1187 - 1199
[7] DX-88 a recombinant inhibitor of human plasma kallikrein. Efficacy and safety in hereditary and acquired angioedema
Cicardi, M
Gonzalez-Quevedo, T
Caballero, T
Bork, K
Williams, A
[J]. MOLECULAR IMMUNOLOGY, 2003, 40 (2-4) : 197 - 198
[8] DX-88 a recombinant inhibitor of human plasma kallikrein. Evalation of efficacy and safety in patients with hereditary angioedema
Williams, T
Cicardi, M
Bork, K
Gonzalez-Quevedo, T
Caballero, T
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (04) : 908 - 908
[9] Results of a repeat-dosing study of intravenous and subcutaneous administration of ecallantide (DX-88), a recombinant plasma kallikrein inhibitor, in patients with hereditary angioedema.
Lumry, W.
Li, H.
Schneider, L.
Leflein, J.
Craig, T.
Morrison, J.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 98 (01) : A29 - A29
[10] C1 Esterase Inhibitor (Human) for the Treatment of Acute Hereditary Angioedema
Rodrigues Valle, Solange Oliveira
Franca, Alfeu Tavares
Campos, Regis A.
Grumach, Anete Sevciovic
[J]. CLINICAL MEDICINE INSIGHTS-BLOOD DISORDERS, 2011, 4 : 421 - 430

← 1 2 3 4 5 →